Observational studyBMC cancer2022

Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States.

Rohan Medhekar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.